HLA B27 Disease Association

Whole blood

Adult tube

0.5 mL (Note: This volume does not allow for repeat testing.)

Lavender-top (EDTA) tube

Evaluate spondyloarthritis and other disorders associated with HLA-B27

Regarding whole blood specimens, an adequate test requires the presence of intact lymphocytes at the time of testing. Even taking appropriate precautions, an occasional specimen will not be satisfactory for testing. In such cases, fresh blood should be drawn for retesting.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).

Polymerase chain reaction (PCR)/sequence-specific oligonucleotide probes (SSOP)

This test is a class I antigen level test.

The generic sequence coding for HLA-B27 is probed and reported as either P (positive) if it is present or N (negative) if it is absent.

HLA-B27 is strongly associated with ankylosing spondylitis (Marie-Strumpell disease). HLA-B27 shares homology with a Klebsiella protein and may imply a bacterial pathogenesis to ankylosing spondylitis. A patient with consistent clinical and radiographic findings who is B27-positive has a greater chance of having or developing ankylosing spondylitis than a negative patient. The antigen is not causative, however, and 10% of normal subjects are B27-positive. This test should not be considered a screening procedure for ankylosing spondylitis. The antigen is less strongly associated with Reiter syndrome and other arthritides than with ankylosing spondylitis. It has been linked with congenital deficiency of C₄ and C₂, and with adrenal hyperplasia.